glp 1 covered by insurance for weight loss Why payers are hesitant to cover GLP-1 drugs Major insurance changes are coming

Clinically, that means two patients on BPC-157 or on a peptide stack may be receiving completely different molecules and doses, with unpredictable risk

J Chromatogr B, 2003;792(1):7382

#ScienceNews #NovoNordiskFoundation #Alzheimers #Parkinsons #PrecisionMedicine #Metabolism #Neurology #MedicalResearch To view or add a comment, sign in Im happy to share our latest research: Alcohol-fluoxetine co-treatment drives gut dysbiosis and intestinal barrier disruption with consequences for neuroimmune signaling in male rats. Alcohol use disorder and depression frequently coexist, yet little is known about how alcohol and antidepressant treatment interact through the gut-brain axis

10.1039/D4RA07646J 112 NidorfS